<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix Announces Receipt of CLIA Registration Number

    Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .

    Biodesix Names Paul J Beresford, Formerly of Roche Diagnostics, as Vice President, Business Development and Stategic Marketing

    Biodesix announced that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing.

    VeriStrat® Outcomes Data in Lung Cancer to be Presented at IASLC/ESMO 2nd European Lung Cancer Conference

    Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.

    Biodesix Names Douglas E. Swan, formerly of Imclone Systems Incorporated, as Vice President, Commercial Operations

    Biodesix announced today that Douglas E. Swan has joined the company as Vice President, Commercial Operations, reporting directly to David Brunel, CEO

    Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

    Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.

    Biodesix CEO to Present at Personalized Medicine Partnerships Conference

    Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.

    Biodesix Selected as a Colorado Company to Watch

    Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.

    Biodesix Secures $10 Million in Series B-1 Funding

    Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.

    Biodesix Completes Series C Financing and Receives Grant

    Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.

    1 2 3 4